GeneTx Biotherapeutics has received institutional review board approval to start a Phase 1/2 clinical trial…
Vanessa Pataia
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.